fda declares semaglutide shortage resolved february 2025 says Wegovy and Ozempic resolved; Hims & Hers stock falls Lots of talk about F

Most bruising is cosmetic only and poses no threat to your weight loss progress

CagriSema is Novos next-generation obesity drug candidate, still in clinical trials so not available to the public

As GLP-1 receptor agonists gain wider use for metabolic disease and weight management, dermatologists, primary care clinicians, researchers, and patients are seeking clear information about possible cutaneous effects, rare adverse events, and potential therapeutic interactions

No medication is appropriate for every patient

This test, available as a $99 add-on after your first month of treatment, reveals your biological predisposition to GLP-1 response and hunger pathway sensitivity